InterMune Stock Price, News & Analysis (NASDAQ:ITMN)

Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About InterMune (NASDAQ:ITMN)

InterMune logoInterMune, Inc. (InterMune) is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases. Pulmonology is the field of medicine concerned with the diagnosis and treatment of lung conditions. The Company has a product in pulmonology, pirfenidone, which is an orally active, small molecule compound. On January 2, 2013, it began the commercial launch of Esbriet in Canada. IPF is a disease characterized by progressive scarring, or fibrosis, of the lungs, which leads to their deterioration and destruction. The prognosis is poor for patients with IPF, which occurs primarily in persons 40 to 70 years old with a median survival time from diagnosis of two to five years. Pirfenidone in Japan is sold by Shionogi under the brand name Pirespa. Pirfenidone in India is sold by Cipla Ltd. under the brand name Pirfenex, and in China is sold by Shanghai Genomics. In September 2014, Roche Holding AG acquired InterMune.

Receive ITMN News and Ratings via Email

Sign-up to receive the latest news and ratings for ITMN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:ITMN
CUSIP45884X10
WebN/A
Phone+1-415-4662200

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A

InterMune (NASDAQ:ITMN) Frequently Asked Questions

What is InterMune's stock symbol?

InterMune trades on the NASDAQ under the ticker symbol "ITMN."

Who are some of InterMune's key competitors?

How do I buy InterMune stock?

Shares of InterMune can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact InterMune?

InterMune's mailing address is 3280 Bayshore Blvd, BRISBANE, CA 94005-1021, United States. The biotechnology company can be reached via phone at +1-415-4662200.


MarketBeat Community Rating for InterMune (ITMN)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  206 (Vote Outperform)
Underperform Votes:  171 (Vote Underperform)
Total Votes:  377
MarketBeat's community ratings are surveys of what our community members think about InterMune and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

InterMune (NASDAQ:ITMN) Analyst Ratings History


No equities research coverage for this company has been tracked by MarketBeat

Earnings

InterMune (NASDAQ:ITMN) Earnings History and Estimates Chart

Earnings by Quarter for InterMune (NASDAQ:ITMN)

InterMune (NASDAQ ITMN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2014Q214($0.56)($0.72)$33.96 million$35.70 millionViewListenView Earnings Details
5/1/2014Q114($0.62)($0.59)$28.24 million$30.30 millionViewListenView Earnings Details
7/24/2013Q2 2013($0.70)($0.77)$12.95 million$14.40 millionViewListenView Earnings Details
4/24/2013Q1 2013($0.73)($0.64)$10.53 million$10.53 millionViewListenView Earnings Details
2/21/2013Q4 2012($0.87)($0.90)$8.31 million$8.20 millionViewListenView Earnings Details
11/7/2012Q312($0.83)($0.70)$6.31 million$7.50 millionViewN/AView Earnings Details
7/23/2012$0.10$0.01ViewN/AView Earnings Details
4/26/2012($0.70)($0.74)ViewN/AView Earnings Details
2/9/2012($0.71)($0.69)ViewN/AView Earnings Details
11/3/2011($0.72)($0.63)ViewN/AView Earnings Details
8/4/2011($0.62)($0.68)ViewN/AView Earnings Details
4/28/2011($0.78)($0.57)ViewN/AView Earnings Details
2/16/2011$0.64$3.34ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

InterMune (NASDAQ:ITMN) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for InterMune (NASDAQ:ITMN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

InterMune (NASDAQ ITMN) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for InterMune (NASDAQ:ITMN)

InterMune (NASDAQ ITMN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/2/2014Andrew Kenneth William PowellEVPSell7,500$73.47$551,025.00View SEC Filing  
8/13/2014Paul D ArataEVPSell7,500$50.00$375,000.00View SEC Filing  
8/11/2014John HodgmanCFOSell4,724$43.05$203,368.20View SEC Filing  
8/7/2014Daniel G WelchCEOSell171,025$44.98$7,692,704.50View SEC Filing  
7/17/2014Paul D ArataEVPSell2,382$41.00$97,662.00View SEC Filing  
7/15/2014Jonathan A LeffEVPSell35,000$43.08$1,507,800.00View SEC Filing  
6/18/2014Sean P NolanEVPSell10,000$47.10$471,000.00View SEC Filing  
6/16/2014Daniel G WelchCEOSell15,000$45.02$675,300.00View SEC Filing  
6/13/2014Sean P NolanEVPSell20,000$42.80$856,000.00View SEC Filing  
6/4/2014Daniel G WelchCEOSell3,914$39.19$153,389.66View SEC Filing  
6/3/2014John HodgmanCFOSell1,201$38.78$46,574.78View SEC Filing  
6/3/2014Jonathan A LeffEVPSell1,153$38.78$44,713.34View SEC Filing  
5/30/2014Daniel G WelchCEOSell4,565$40.06$182,873.90View SEC Filing  
5/29/2014David S KabakoffDirectorSell5,000$39.56$197,800.00View SEC Filing  
5/27/2014Daniel G WelchCEOSell41,493$40.03$1,660,964.79View SEC Filing  
5/19/2014Sean NolanEVPSell7,500$39.50$296,250.00View SEC Filing  
5/8/2014Sean NolanVPSell2,644$35.85$94,787.40View SEC Filing  
5/6/2014Daniel WelchCEOSell60,432$34.76$2,100,616.32View SEC Filing  
3/4/2014Jonathan LeffEVPSell27,361$30.95$846,822.95View SEC Filing  
3/4/2014Nepi Giacomo DiDirectorSell70,000$30.84$2,158,800.00View SEC Filing  
1/10/2014Daniel WelchCEOSell50,000$17.00$850,000.00View SEC Filing  
12/2/2013Daniel WelchCEOSell20,000$13.99$279,800.00View SEC Filing  
10/1/2013Daniel G WelchCEOSell70,000$15.43$1,080,100.00View SEC Filing  
8/30/2013David KabakoffDirectorSell10,002$14.82$148,229.64View SEC Filing  
8/27/2013Angus RussellDirectorBuy6,600$14.53$95,898.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

InterMune (NASDAQ ITMN) News Headlines

Source:
DateHeadline
Ex-InterMune executive, friend found liable for insider tradingEx-InterMune executive, friend found liable for insider trading
uk.finance.yahoo.com - November 14 at 5:56 PM
The Push and Pull of Gender for Muslims at the HajjThe Push and Pull of Gender for Muslims at the Hajj
www.nytimes.com - September 15 at 6:08 PM
Netflixs White Helmets Highlights a Syrian Rescue Group on the Front LineNetflix's 'White Helmets' Highlights a Syrian Rescue Group on the Front Line
www.nbcnews.com - September 15 at 6:08 PM
Indians, Some Seeking Brighter Fortunes, Celebrate Vibrant Ganesh FestivalIndians, Some Seeking Brighter Fortunes, Celebrate Vibrant Ganesh Festival
www.nytimes.com - September 15 at 6:08 PM
Roche to buy California biotech firm InterMune for $8.3 billionRoche to buy California biotech firm InterMune for $8.3 billion
www.latimes.com - August 24 at 7:29 PM

SEC Filings

InterMune (NASDAQ:ITMN) SEC Filings

DateFilerForm TypeView

Social Media

Financials

InterMune (NASDAQ:ITMN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

InterMune (NASDAQ ITMN) Stock Chart for Monday, December, 11, 2017

Loading chart…

This page was last updated on 12/11/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.